Targeting matriptase in breast cancer abrogates tumour progression via impairment of stromal-epithelial growth factor signalling

Nature Communications

Volumn 6, Issue , 2015, Pages

  Zoratti, Gina L ^a   Tanabe, Lauren M ^a   Varela, Fausto A ^a   Murray, Andrew S ^a   Bergum, Christopher ^a   Colombo, Éloïc ^b   Lang, Julie E ^c   Molinolo, Alfredo A ^d   Leduc, Richard ^b   Marsault, Eric ^b   Boerner, Julie ^a   List, Karin ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF SHERBROOKE   (Canada)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH FACTOR; MATRIPTASE; SCATTER FACTOR RECEPTOR; STROMAL EPITHELIAL GROWTH FACTOR; UNCLASSIFIED DRUG; GAB1 PROTEIN, HUMAN; GAB1 PROTEIN, MOUSE; MEMBRANE PROTEIN; PHOSPHOPROTEIN; PRO-HEPATOCYTE GROWTH FACTOR; PROTEIN KINASE B; PROTEIN PRECURSOR; SCATTER FACTOR; SERINE PROTEINASE; SIGNAL TRANSDUCING ADAPTOR PROTEIN; ST14 PROTEIN, HUMAN; ST14 PROTEIN, MOUSE;

CANCER; GENE EXPRESSION; GENETIC VARIATION; GERM CELL; GROWTH RATE; MEMBRANE; MOLECULAR ANALYSIS; SIGNALING;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY SPECIFICITY; APOPTOSIS; ARTICLE; BREAST CANCER; BREAST EPITHELIUM; CANCER CELL; CARCINOGENESIS; CELL PROLIFERATION; CONTROLLED STUDY; EXON; FIBROBLAST; GENE DELETION; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH; TUMOR VOLUME; ANIMAL; BREAST TUMOR; CARCINOMA; CELL CULTURE TECHNIQUE; EXPERIMENTAL MAMMARY NEOPLASM; FEMALE; GENETICS; KNOCKOUT MOUSE; METABOLISM; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE; TUMOR CELL LINE; WESTERN BLOTTING;

MUS;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; BLOTTING, WESTERN; BREAST NEOPLASMS; CARCINOMA; CELL CULTURE TECHNIQUES; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; HEPATOCYTE GROWTH FACTOR; HUMANS; IMMUNOHISTOCHEMISTRY; MAMMARY NEOPLASMS, ANIMAL; MAMMARY NEOPLASMS, EXPERIMENTAL; MEMBRANE PROTEINS; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; PHOSPHOPROTEINS; PROTEIN PRECURSORS; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-MET; SERINE ENDOPEPTIDASES; SIGNAL TRANSDUCTION;

EID: 84928164267     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms7776     Document Type: Article

References (57)

1. Bhatt, A. S. et al. Quantitation of membrane type serine protease 1 (MT-SP1) in transformed and normal cells. Biol. Chem. 384, 257-266 (2003).
2. Lin, C. Y. et al. Characterization of a novel, membrane-bound, 80-kDa matrix-degrading protease from human breast cancer cells. Monoclonal antibody production, isolation, and localization. J. Biol. Chem. 272, 9147-9152 (1997).
3. Oberst, M. et al. Matriptase and HAI-1 are expressed by normal and malignant epithelial cells in vitro and in vivo. Am. J. Pathol. 158, 1301-1311 (2001).
4. Jin, J. S. et al. Expression of the serine protease, matriptase, in breast ductal carcinoma of Chinese women: correlation with clinicopathological parameters. Histol. Histopathol. 22, 305-309 (2007).
5. Bergum, C., Zoratti, G., Boerner, J. & List, K. Strong expression association between matriptase and its substrate prostasin in breast cancer. J. Cell Physiol. 227, 1604-1609 (2012).
6. List, K. et al. Matriptase/MT-SP1 is required for postnatal survival, epidermal barrier function, hair follicle development, and thymic homeostasis. Oncogene 21, 3765-3779 (2002).
7. List, K. et al. Loss of proteolytically processed filaggrin caused by epidermal deletion of Matriptase/MT-SP1. J. Cell Biol. 163, 901-910 (2003).
8. Weidner, K. M. et al. Evidence for the identity of human scatter factor and human hepatocyte growth factor. Proc. Natl Acad. Sci. USA 88, 7001-7005 (1991).
9. Nakamura, T. et al. Molecular cloning and expression of human hepatocyte growth factor. Nature 342, 440-443 (1989).
10. Stoker, M., Gherardi, E., Perryman, M. & Gray, J. Scatter factor is a fibroblast-derived modulator of epithelial cell mobility. Nature 327, 239-242 (1987).
11. Cooper, C. S. et al. Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature 311, 29-33 (1984).
12. Bottaro, D. P. et al. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 251, 802-804 (1991).
13. Kang, J. Y. et al. Tissue microarray analysis of hepatocyte growth factor/Met pathway components reveals a role for Met, matriptase, and hepatocyte growth factor activator inhibitor 1 in the progression of node-negative breast cancer. Cancer Res. 63, 1101-1105 (2003).
14. Camp, R. L., Rimm, E. B. & Rimm, D. L. Met expression is associated with poor outcome in patients with axillary lymph node negative breast carcinoma. Cancer 86, 2259-2265 (1999).
15. Ghoussoub, R. A. et al. Expression of c-met is a strong independent prognostic factor in breast carcinoma. Cancer 82, 1513-1520 (1998).
16. Gallego, M. I., Bierie, B. & Hennighausen, L. Targeted expression of HGF/SF in mouse mammary epithelium leads to metastatic adenosquamous carcinomas through the activation of multiple signal transduction pathways. Oncogene 22, 8498-8508.
17. Liang, T. J., Reid, A. E., Xavier, R., Cardiff, R. D. & Wang, T. C. Transgenic expression of tpr-met oncogene leads to development of mammary hyperplasia and tumors. J. Clin. Invest. 97, 2872-2877 (1996).
18. Buchanan, I. M. et al. Radiosensitization of glioma cells by modulation of Met signalling with the hepatocyte growth factor neutralizingantibody, AMG102. J. Cell Mol. Med. 15, 1999-2006 (2011).
19. Li, Y. et al. c-Met targeting enhances the effect of irradiation and chemical agents against malignant colon cells harboring a KRAS mutation. PLoS One 9, e113186 (2014).
20. Bhardwaj, V. et al. Modulation of c-Met signaling and cellular sensitivity to radiation: potential implications for therapy. Cancer 119, 1768-1775 (2013).
21. Previdi, S., Abbadessa, G., Dalò, F., France, D. S. & Broggini, M. Breast cancer-derived bone metastasis can be effectively reduced through specific c-MET inhibitor tivantinib (ARQ 197) and shRNA c-MET knockdown. Mol. Cancer Ther. 11, 214-223 (2012).
22. Gherardi, E., Birchmeier, W., Birchmeier, C. & Vande Woude, G. Targeting MET in cancer: rationale and progress. Nat. Rev. Cancer 12, 89-103 (2012).
23. Guy, C. T., Cardiff, R. D. & Muller, W. J. Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol. Cell Biol. 12, 954-961 (1992).
24. Lin, E. Y. et al. Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. Am. J. Pathol. 163, 2113-2126 (2003).
25. List, K., Szabo, R., Molinolo, A., Nielsen, B. S. & Bugge, T. H.Delineation of matriptase protein expression by enzymatic gene trapping suggests diverging roles in barrier function, hair formation, and squamous cell carcinogenesis. Am. J. Pathol. 168, 1513-1525 (2006).
26. List, K., Hobson, J. P., Molinolo, A. & Bugge, T. H. Co-localization of the channel activating protease prostasin/(CAP1/PRSS8) with its candidate activator, matriptase. J. Cell Physiol. 213, 237-245 (2007).
27. List, K. et al. Autosomal ichthyosis with hypotrichosis syndrome displays low matriptase proteolytic activity and is phenocopied in ST14 hypomorphic mice. J. Biol. Chem. 282, 36714-36723 (2007).
28. Lee, S. L., Dickon, R. B. & Lin, C. Y. Activation of hepatocyte growth factor and urokinase/plasminogen activator by matriptase, an epithelial membrane serine protease. J. Biol. Chem. 75, 36720-36725 (2000).
29. Förbs, D. et al. In vitro inhibition of matriptase prevents invasive growth of cell lines of prostate and colon carcinoma. Int. J. Oncol. 27, 1061-1070 (2005).
30. Niranjan, B. et al. HGF/SF: a potent cytokine for mammary growth, morphogenesis and development. Development 121, 2897-2908 (1995).
31. D'Angelo, F. et al. Macrophages promote epithelial repair through hepatocyte growth factor secretion. Clin. Exp. Immunol. 174, 60-72 (2013).
32. Mizuno, S. & Nakamura, T. HGF-MET cascade, a key target for inhibiting cancer metastasis: the impact of NK4 discovery on cancerbiology and therapeutics. Int. J. Mol. Sci. 14, 888-919 (2013).
33. Feil, R., Wagner, J., Metzger, D. & Chambon, P. Regulation of Cre recombinase activity by mutated estrogen receptor ligand-binding domains. Biochem. Biophys. Res. Commun. 237, 752-757 (1997).
34. List, K. et al. Epithelial integrity is maintained by a matriptase-dependent proteolytic pathway. Am. J. Pathol. 175, 1453-1463 (2009).
35. Kuperwasser, C. et al. Reconstruction of functionally normal and malignant human breast tissues in mice. Proc. Natl Acad. Sci. USA 101, 4966-4971 (2004).
36. Sachs, M. et al. Essential role of Gab1 for signaling by the c-Met receptor in vivo. J. Cell Biol. 150, 1375-1384 (2000).
37. Takeuchi, T. et al. Cellular localization of membrane-type serine protease 1 and identification of protease-activated receptor-2 and single-chain urokinase-type plasminogen activator as substrates. J. Biol. Chem. 275, 26333-26342 (2000).
38. Owen, K. A. et al. Pericellular activation of hepatocyte growth factor by the transmembrane serine proteases matriptase and hepsin, but not by the membrane-associated protease uPA. Biochem. J. 426, 219-228 (2010).
39. Mars, W. M., Zarnegar, R. & Michalopoulos, G. K. Activation of hepatocyte growth factor by the plasminogen activators uPA and tPA. Am. J. Pathol. 143, 949-958 (1993).
40. Mars, W. M., Kim, T. H., Stolz, D. B., Liu, M. L. & Michalopoulos, G. K. Presence of urokinase in serum-free primary rat hepatocyte cultures and its role in activating hepatocyte growth factor. Cancer Res. 56, 2837-2843 (1996).
41. Naldini, L. et al. Extracellular proteolytic cleavage by urokinase is required for activation of hepatocyte growth factor/scatter factor. EMBO J. 13, 4825-4833 (1992).
42. Benaud, C., Dickson, R. B. & Lin, C. Y. Regulation of the activity of matriptase on epithelial cell surfaces by a blood-derived factor. Eur. J. Biochem. 268, 1439-1447 (2001).
43. Szabo, R. et al. Potent inhibition and global co-localization implicate the transmembrane Kunitz-type serine protease inhibitor hepatocyte growth factor activator inhibitor-2 in the regulation of epithelial matriptase activity. J. Biol. Chem. 283, 29495-29504 (2008).
44. Szabo, R. et al. Regulation of cell surface protease matriptase by HAI2 is essential for placental development, neural tube closure and embryonic survival in mice. Development 136, 2653-2663 (2009).
45. Szabo, R., Kosa, P., List, K. & Bugge, T. H. Loss of matriptase suppression underlies spint1 mutation-associated ichthyosis and postnatal lethality. Am. J. Pathol. 174, 2015-2022 (2009).
46. Colombo, E. et al. Design and Synthesis of potent, selective inhibitors of matriptase. ACS Med. Chem. Lett. 3, 530-534 (2012).
47. Beaulieu, A. et al. Matriptase proteolytically activates influenza virus and promotes multicycle replication in the human airway epithelium. J. Virol. 87, 4237-4251 (2013).
48. Parr, C. & Jiang, W. G. Expression of hepatocyte growth factor/scatter factor, its activator, inhibitors and the c-Met receptor in human cancer cells. Int. J. Oncol. 19, 857-863 (2001).
49. Bladt, F., Riethmacher, D., Isenmann, S., Aguzzi, A. & Birchmeier, C. Essential role for the c-met receptor in the migration of myogenic precursor cells into the limb bud. Nature 376, 768-771 (1995).
50. Uehara, Y. et al. Placental defect and embryonic lethality in mice lacking hepatocyte growth factor/scatter factor. Nature 373, 702-705 (1995).
51. Itoh, H. et al. Regeneration of injured intestinal mucosa is impaired in hepatocyte growth factor activator-deficient mice. Gastroenterology 127, 1423-1435 (2004).
52. Netzel-Arnett, S. et al. Matriptase protects against experimental colitis and promotes intestinal barrier recovery. Inflamm. Bowel Dis. 18, 1303-1314 (2012).
53. Basel-Vanagaite, L. et al. Autosomal recessive ichthyosis with hypotrichosis caused by a mutation in ST14, encoding type II transmembrane serine protease matriptase. Am. J. Hum. Genet. 80, 467-477 (2007).
54. Simian, M. et al. The interplay of matrix metalloproteinases, morphogens and growth factors is necessary for branching of mammary epithelial cells. Development 128, 3117-3131 (2001).
55. Mueller, K. L. et al. Fibroblast-secreted hepatocyte growth factor mediates epidermal growth factor receptor tyrosine kinase inhibitor resistance in triple-negative breast cancers through paracrine activation of Met. Breast Cancer Res. 12, R104 (2012).
56. Victor, B. C., Anbalagan, A., Mohamed, M. M., Sloane, B. F. & Cavallo-Medved, D. Inhibition of cathepsin B activity attenuates extracellular matrix degradation and inflammatory breast cancer invasion. Breast Cancer Res. 13, R115 (2011).
57. Friis, S. et al. A matriptase-prostasin reciprocal zymogen activation complex with unique features: prostasin as a non-enzymatic co-factor for matriptase activation. J. Biol. Chem. 288, 19028-19039 (2013).